Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jazz Pharmaceuticals plc (Nasdaq: JAZZ) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, alongside AI-assisted summaries to help interpret complex documents. Jazz, an Ireland-incorporated global biopharma company, files current and periodic reports as an issuer with ordinary shares listed on The Nasdaq Stock Market LLC under the symbol JAZZ.
Investors and researchers can review Form 8-K filings that report material events, including clinical trial milestones for products such as Ziihera (zanidatamab-hrii), financial results for specific quarters, executive and board changes, and legal settlements related to its sleep disorder and epilepsy franchises. These current reports often reference accompanying press releases that provide additional narrative detail on oncology and neuroscience developments.
Through this page, users can also locate references to quarterly and annual reports (Forms 10-Q and 10-K when available), which typically contain broader discussions of Jazz’s business, risk factors, pipeline, marketed medicines and financial condition. In addition, proxy materials and shareholder meeting results, such as votes on director elections and auditor appointments, are accessible for those tracking governance matters.
Stock Titan’s AI tools are designed to highlight key points from lengthy filings, helping users quickly identify sections related to oncology programs, neuroscience assets, royalty and settlement agreements, or capital markets activity. Where applicable, investors can also review insider-related filings such as Forms 3, 4 and 5 to monitor transactions in JAZZ ordinary shares by directors and officers, as reported to the SEC.
By combining real-time EDGAR updates with AI-generated overviews, this page offers a practical way to follow how Jazz Pharmaceuticals documents its clinical progress, corporate actions and financial reporting obligations in the U.S. regulatory framework.
Jazz Pharmaceuticals (JAZZ) has filed a Form 144 indicating that Chairman & CEO Bruce C. Cozadd intends to sell up to 9,000 common shares through Merrill Lynch on or about 1 Aug 2025. Based on the reference price in the filing, the sale is valued at approximately $1.10 million, equal to ~0.01% of the company’s 61.6 million shares outstanding.
The shares were acquired via equity-compensation grants made between December 2021 and February 2022. Over the past three months Cozadd has already sold 2,500 shares for gross proceeds of $276.6 k. The filer certifies under Rule 144 that he possesses no undisclosed material adverse information.
While such sales are common for liquidity or tax purposes, investors often view continued insider selling—especially by the CEO—as a potential signal of tempered confidence. Market watchers may track any additional Form 4 filings or 10b5-1 plan disclosures for context.
Jazz Pharmaceuticals plc (JAZZ) has issued a DEFA14A supplement to its 2025 proxy materials outlining a planned CEO succession and related compensation adjustments.
- Leadership transition: President & COO Renee Gala will become President & Chief Executive Officer on 11 Aug 2025. Current CEO Bruce Cozadd will remain until that date, then serve in a transition role through 12 Sep 2025 before retiring while continuing as Board Chair.
- Board expansion: Board size increases from 12 to 13 seats; Ms. Gala will join as a Class I director with a term expiring in 2027.
- Compensation changes: Ms. Gala’s annual base salary rises to $1.2 million (from $0.9 million) and her target cash bonus to 110% of salary (from 80%), effective 11 Aug 2025.
- Equity awards: One-time promotion grant valued at ~$6.5 million (33% RSUs, 67% PSUs) in addition to her previously granted 2025 annual equity award of ~$6 million.
- Enhanced severance: Cash severance on involuntary termination without cause (outside a change-in-control period) increases to 150% of base salary plus up to 18 months of COBRA premiums (previously 100% salary and 12 months premiums).
- Voting impact: No changes to the proposals or proxy card for the 24 Jul 2025 AGM; shareholders are encouraged to review both the original proxy and this supplement.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) disclosed in an 8-K that its Board appointed current President & COO Renee Gala as President & Chief Executive Officer effective 11 Aug 2025. The Board will expand from 12 to 13 members and seat Gala as a Class I director through the 2027 AGM. Outgoing CEO Bruce Cozadd will remain CEO until 11 Aug 2025, shift to a transition role until 12 Sep 2025, then retire while continuing as non-executive Chair.
Gala’s compensation package was revised: base salary rises 33 % to $1.2 million; target annual bonus increases to 110 % of salary (from 80 %). She will also receive a one-time $6.5 million promotion equity grant (33 % RSUs vesting annually over four years; 67 % PSUs tied to 2025 performance metrics) on top of her previously granted $6 million 2025 annual equity award.
Severance protections were enhanced: in an involuntary termination without cause outside a change-in-control window, Gala is now entitled to a lump-sum payment equal to 150 % of base salary (previously 100 %) and up to 18 months of company-paid COBRA premiums (previously 12 months).
No financial metrics, earnings guidance, or strategic updates were included. A confirming press release (Exhibit 99.1) was furnished under Item 7.01.